R8404
Rufinamide
≥98% (HPLC), powder
别名:
1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C10H8F2N4O
化学文摘社编号:
分子量:
238.19
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
产品名称
Rufinamide, ≥98% (HPLC), powder
InChI key
POGQSBRIGCQNEG-UHFFFAOYSA-N
SMILES string
NC(=O)c1cn(Cc2c(F)cccc2F)nn1
InChI
1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)
assay
≥98% (HPLC)
form
powder
color
white
solubility
DMSO: 9 mg/mL
originator
Novartis
storage temp.
−20°C
Quality Level
Gene Information
正在寻找类似产品? 访问 产品对比指南
Application
Rufinamide has been used to test its analgesic effect on neuropathic pain in spared nerve injury (SNI) model.
Biochem/physiol Actions
Broad-spectrum anticonvulsant.
Rufinamide may elicit inhibition of the sodium channels and block action potential generation. This property makes it an antiepileptic drug for treating epilepsy disorders like Lennox-Gastaut syndrome.
Features and Benefits
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
General description
Effective therapy for partial seizures in adults and childhood seizures in Lennox-Gastaut syndrome.
signalword
Warning
hcodes
Hazard Classifications
Carc. 2 - Repr. 2 - STOT SE 3
target_organs
Central nervous system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
C von Stülpnagel et al.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 16(5), 459-463 (2012-01-24)
We evaluated the long-term efficacy and tolerability of the orphan drug rufinamide (RUF) in children with pharmacoresistant myoclonic-astatic epilepsy (MAE, Doose syndrome). This was a retrospective European multicenter study on eight patients who had started an intention-to-treat trial of RUF
Isabelle Mourand et al.
Epilepsia, 54(1), e5-e8 (2012-07-12)
Rufinamide (RUF) is a novel antiepileptic drug considered as second-line therapy in the treatment of Lennox-Gastaut syndrome. Treatment-emergent adverse events (AEs) have consisted mainly of drowsiness, irritability, vomiting, and loss of appetite. RUF is considered as a "weight-neutral" drug. We
Alberto Verrotti et al.
Pediatric neurology, 44(5), 347-349 (2011-04-13)
Rufinamide is a new orally active antiepileptic drug that has been found to be effective in the treatment of partial seizures and drop attacks associated with Lennox-Gastaut syndrome. We performed a quantitative analysis of the efficacy of this new antiepileptic
Maria G Dahlin et al.
Neuropediatrics, 43(5), 264-270 (2012-09-04)
We examined the influence of age and type of concomitant antiepileptic drugs (AEDs) on the pharmacokinetics of rufinamide (RUF) as well as its efficacy and safety in 51 children with refractory epilepsy. In a retrospective noninterventional survey, dose-to-concentration ratios of
Shahin Hakimian et al.
Expert opinion on pharmacotherapy, 8(12), 1931-1940 (2007-08-19)
Rufinamide (1-[2,6-difluorobenzyl]-1H-1,2,3-triazole-4-carboxamide) is a new anti-epileptic drug with a novel triazole derivative structure. The suspected mechanism of action is limitation of sodium-dependent action potentials, thought to result in a membrane stabilizing effect. Rufinamide is extensively metabolized in the liver by
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持